Growth Metrics

Palvella Therapeutics (PVLA) Gains from Investment Securities (2014 - 2026)

Palvella Therapeutics (PVLA) reported Gains from Investment Securities of $3108.0 for Q1 2026, down 99.65% year-over-year from $892827.0 in Q1 2025, and down 99.89% on a QoQ basis from $2.9 million in Q4 2025.

Palvella Therapeutics (PVLA) has 13 years of Gains from Investment Securities data on file, last reported at $3108.0 in Q1 2026.

  • Quarterly Gains from Investment Securities fell 99.65% year-over-year to $3108.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3108.0 (down 99.65% YoY) and the FY2025 annual result came in at $2.9 million, changed N/A from the prior year.
  • Gains from Investment Securities retreated to $3108.0 in Q1 2026 per PVLA's latest filing, from $2.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.9 million in Q4 2025 and bottomed at -$214000.0 in Q2 2022.
  • The 5-year median for Gains from Investment Securities is $33400.0 (2023), against an average of $500894.6.
  • The widest annual swing landed in 2022, when Gains from Investment Securities slumped 421.95%; it then jumped 12935.72% in 2025.
  • Tracing PVLA's Gains from Investment Securities over 5 years: stood at -$208000.0 in 2022, then soared by 63.46% to -$76000.0 in 2023, then soared by 538.35% to $333145.0 in 2024, then jumped by 775.64% to $2.9 million in 2025, then sank by 99.89% to $3108.0 in 2026.
  • Per Business Quant, the three latest PVLA Gains from Investment Securities figures stand at $3108.0 (Q1 2026), $2.9 million (Q4 2025), and $47800.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Palvella Therapeutics 1.47 Bn 1.21 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 3,108.00
Mar 31, 2026 3,108.00
Dec 31, 2025 2.92 Mn
Dec 31, 2025 2.92 Mn
Sep 30, 2025 47,800.00
Sep 30, 2025 47,800.00
Jun 30, 2025 2.70 Mn
Jun 30, 2025 2.70 Mn
Mar 31, 2025 892,827.00
Mar 31, 2025 892,827.00
Sep 30, 2024 333,145.00
Sep 30, 2024 333,145.00
Jun 30, 2024 -21,000.00
Jun 30, 2024 -21,000.00
Dec 31, 2023 -76,000.00
Dec 31, 2023 -76,000.00
Sep 30, 2023 19,000.00
Sep 30, 2023 19,000.00
Jun 30, 2023 182,000.00
Jun 30, 2023 182,000.00
Mar 31, 2023 -72,000.00
Mar 31, 2023 -72,000.00
Dec 31, 2022 -208,000.00
Dec 31, 2022 -208,000.00
Sep 30, 2022 513,000.00
Sep 30, 2022 513,000.00
Jun 30, 2022 -214,000.00
Jun 30, 2022 -214,000.00
Jun 30, 2021 -41,000.00
Jun 30, 2021 -41,000.00
Mar 31, 2021 41,000.00
Mar 31, 2021 41,000.00
Dec 31, 2020 -764,000.00
Dec 31, 2020 -764,000.00
Sep 30, 2020 636,000.00
Sep 30, 2020 636,000.00
Jun 30, 2020 -243,000.00
Jun 30, 2020 -243,000.00
Mar 31, 2020 -100,000.00
Mar 31, 2020 -100,000.00
Dec 31, 2019 1.25 Mn
Dec 31, 2019 1.25 Mn
Sep 30, 2019 -241,000.00
Sep 30, 2019 -241,000.00
Jun 30, 2019 -147,000.00
Jun 30, 2019 -147,000.00
Mar 31, 2019 298,000.00
Mar 31, 2019 298,000.00
Dec 31, 2018 1.28 Mn
Dec 31, 2018 1.28 Mn
Sep 30, 2018 430,000.00
Sep 30, 2018 430,000.00
Jun 30, 2018 -46,000.00
Jun 30, 2018 -46,000.00
Mar 31, 2018 -8,000.00
Mar 31, 2018 -8,000.00
Dec 31, 2017 -206,000.00
Dec 31, 2017 -206,000.00
Sep 30, 2017 1.95 Mn
Sep 30, 2017 1.95 Mn
Jun 30, 2017 1.26 Mn
Jun 30, 2017 1.26 Mn
Mar 31, 2017 90,000.00
Mar 31, 2017 90,000.00
Dec 31, 2016 1.16 Mn
Dec 31, 2016 1.16 Mn
Dec 31, 2015 450,000.00
Dec 31, 2015 450,000.00
Sep 30, 2015 500,000.00
Sep 30, 2015 500,000.00
Jun 30, 2015 72,235.00
Jun 30, 2015 72,235.00
Mar 31, 2015 25,000.00
Mar 31, 2015 25,000.00
Dec 31, 2014 2.52 Mn
Dec 31, 2014 2.52 Mn
Jun 30, 2014 18.00
Jun 30, 2014 18.00
Mar 31, 2014 18.00
Mar 31, 2014 18.00